Q-omics provides the consensus-scored MTMR7 profile across patient tissues and cancer cell-line models. MTMR7 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MTMR7 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, MTMR7 protein abundance shows 32,096 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, COAD, and GBM as cancer lineages where MTMR7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTMR7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTMR7 survival associations across molecular data types. MTMR7 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTMR7 RNA expression–survival associations across cancer types. High MTMR7 expression shows unfavorable associations in KICH, STAD, MESO and ACC, but favorable associations in LGG and PAAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for MTMR7 RNA expression.
This table summarizes MTMR7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MTMR7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTMR7 shows lower tumor expression in COAD, KIRP, KICH, LUSC and KIRC and higher tumor expression in LIHC. The COAD box plot shows higher MTMR7 RNA expression in normal versus tumor tissue (log2 FC = −0.309, t-test p < 0.001).
This table shows molecular features associated with MTMR7 in patient tissues and cancer cell lines. In patient samples, MTMR7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MTMR7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
